First Patient Enrolled In GenSpera G-202 Phase 2 Glioblastoma Trial
3/18/2014 9:32:10 AM
SAN ANTONIO--(BUSINESS WIRE)--GenSpera, Inc. (OTCQB:GNSZ) announced that the first patient was enrolled in the Phase II clinical trial of its lead compound, G-202, in patients who have glioblastoma multiforme (GBM), the most prevalent type of primary brain cancer. The trial is being conducted at UC San Diego Moores Cancer Center. This Phase II G-202 trial will treat up to 34 patients with GBM that has progressed or recurred after at least one other treatment.
Help employers find you! Check out all the jobs and post your resume.
comments powered by